UPDATE 1-Roche: Tecentriq cocktail slows kidney cancer progression
December 11, 2017 at 01:30 AM EST
ZURICH, Dec 11 (Reuters) - Combining Roche's Tecentriq immunotherapy with its older drug Avastin reduced the risk of disease worsening or death (PFS) for the initial treatment of advanced kidney cancer in some patients, the Swiss drugmaker said on Monday